Inhibition of RIPK1 can effectively ameliorate the pathologies and promote remyelination in various neurodegenerative diseases including MS [8, 17] and amyotrophic lateral sclerosis (ALS) [17, 18] mainly mediated by protecting oligodendrocytes from necroptosis [8, 13]. Here, RIPK1 is linked to amyotrophic lateral sclerosis.